Risk factors
ADC Therapeutics (ADCT) risk factors
Item 1A of every ADC Therapeutics S.A. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors58 risks6 new2 dropped14 reworded
New trade tariffs and FDA employment reductions introduce external headwinds to manufacturing and regulatory approvals. The HCR Agreement now imposes a $150 million to $200 million change in control fee. Swiss tax loss carryforwards decreased from $1,059 million to $1,009 million.
Filed Mar 10, 2026 - FY2024 10-K risk factors54 risks
ADCT faces concentration risks primarily around ZYNLONTA, heavy debt covenants, and complex international tax and manufacturing structures.
Filed Mar 27, 2025